| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 145 | 2026 | 203 | 18.240 |
Why?
|
| Antirheumatic Agents | 15 | 2026 | 37 | 3.920 |
Why?
|
| Rheumatic Diseases | 5 | 2026 | 12 | 2.510 |
Why?
|
| Hydroxychloroquine | 12 | 2026 | 19 | 2.350 |
Why?
|
| Puerto Rico | 33 | 2026 | 1413 | 2.160 |
Why?
|
| Arthritis, Rheumatoid | 6 | 2023 | 58 | 2.160 |
Why?
|
| Immunosuppressive Agents | 11 | 2020 | 94 | 2.100 |
Why?
|
| Rheumatology | 8 | 2026 | 19 | 2.000 |
Why?
|
| Severity of Illness Index | 37 | 2026 | 719 | 1.970 |
Why?
|
| Middle Aged | 96 | 2026 | 12222 | 1.890 |
Why?
|
| Female | 151 | 2026 | 24698 | 1.790 |
Why?
|
| Humans | 193 | 2026 | 43102 | 1.740 |
Why?
|
| Genetic Predisposition to Disease | 43 | 2016 | 734 | 1.720 |
Why?
|
| Adult | 119 | 2026 | 13872 | 1.680 |
Why?
|
| Fibromyalgia | 4 | 2016 | 11 | 1.420 |
Why?
|
| Disease Progression | 23 | 2026 | 667 | 1.410 |
Why?
|
| Male | 127 | 2026 | 23409 | 1.410 |
Why?
|
| Polymorphism, Single Nucleotide | 42 | 2017 | 863 | 1.390 |
Why?
|
| Lupus Nephritis | 13 | 2014 | 26 | 1.360 |
Why?
|
| Cyclophosphamide | 8 | 2021 | 59 | 1.270 |
Why?
|
| Methylprednisolone | 7 | 2018 | 17 | 1.270 |
Why?
|
| Polyarteritis Nodosa | 2 | 2021 | 4 | 1.210 |
Why?
|
| Treatment Outcome | 18 | 2026 | 1604 | 1.140 |
Why?
|
| Diabetes Mellitus | 4 | 2021 | 539 | 1.040 |
Why?
|
| Cohort Studies | 45 | 2023 | 1759 | 1.010 |
Why?
|
| Leprosy | 1 | 2026 | 4 | 0.970 |
Why?
|
| Retinal Diseases | 1 | 2026 | 20 | 0.970 |
Why?
|
| Chikungunya virus | 3 | 2022 | 18 | 0.870 |
Why?
|
| Gingivitis | 1 | 2024 | 9 | 0.870 |
Why?
|
| Scleroderma, Systemic | 2 | 2014 | 12 | 0.830 |
Why?
|
| Quality of Life | 9 | 2023 | 616 | 0.810 |
Why?
|
| Autoantibodies | 9 | 2022 | 117 | 0.800 |
Why?
|
| Vasculitis | 2 | 2013 | 4 | 0.780 |
Why?
|
| Cryoglobulinemia | 2 | 2013 | 3 | 0.780 |
Why?
|
| Prednisone | 10 | 2022 | 31 | 0.770 |
Why?
|
| Diabetes Complications | 2 | 2021 | 102 | 0.740 |
Why?
|
| Elbow Joint | 1 | 2022 | 2 | 0.740 |
Why?
|
| Cross-Sectional Studies | 14 | 2026 | 3156 | 0.740 |
Why?
|
| Multivariate Analysis | 22 | 2015 | 638 | 0.700 |
Why?
|
| Haplotypes | 25 | 2015 | 197 | 0.690 |
Why?
|
| Arthritis, Infectious | 1 | 2021 | 8 | 0.690 |
Why?
|
| Abdominal Pain | 2 | 2021 | 24 | 0.680 |
Why?
|
| Sjogren's Syndrome | 1 | 2020 | 1 | 0.670 |
Why?
|
| Back Pain | 1 | 2021 | 32 | 0.670 |
Why?
|
| Cardiac Tamponade | 3 | 2015 | 6 | 0.660 |
Why?
|
| Case-Control Studies | 23 | 2021 | 1285 | 0.650 |
Why?
|
| Venous Thrombosis | 5 | 2014 | 30 | 0.650 |
Why?
|
| Retinopathy of Prematurity | 1 | 2020 | 25 | 0.640 |
Why?
|
| Comorbidity | 9 | 2020 | 737 | 0.640 |
Why?
|
| Glucocorticoids | 6 | 2013 | 91 | 0.630 |
Why?
|
| Antiphospholipid Syndrome | 3 | 2016 | 5 | 0.630 |
Why?
|
| Longitudinal Studies | 30 | 2023 | 1063 | 0.610 |
Why?
|
| Arthritis | 2 | 2018 | 18 | 0.590 |
Why?
|
| Aged | 18 | 2026 | 8214 | 0.590 |
Why?
|
| Young Adult | 27 | 2022 | 5080 | 0.580 |
Why?
|
| Arthralgia | 2 | 2022 | 12 | 0.570 |
Why?
|
| Fatigue | 4 | 2021 | 100 | 0.570 |
Why?
|
| United States | 43 | 2021 | 5205 | 0.570 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2017 | 187 | 0.560 |
Why?
|
| Arthritis, Gouty | 1 | 2018 | 1 | 0.560 |
Why?
|
| Sacroiliac Joint | 1 | 2018 | 3 | 0.560 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2018 | 7 | 0.560 |
Why?
|
| Colchicine | 1 | 2018 | 15 | 0.560 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2014 | 89 | 0.550 |
Why?
|
| HLA Antigens | 2 | 2017 | 27 | 0.550 |
Why?
|
| Genetic Load | 1 | 2017 | 2 | 0.540 |
Why?
|
| Hepatic Artery | 1 | 2017 | 2 | 0.520 |
Why?
|
| Thrombocytopenia | 4 | 2012 | 23 | 0.520 |
Why?
|
| Follow-Up Studies | 10 | 2026 | 1067 | 0.520 |
Why?
|
| Anemia, Hemolytic | 3 | 2012 | 8 | 0.520 |
Why?
|
| Kidney Diseases | 5 | 2011 | 172 | 0.510 |
Why?
|
| Myositis | 2 | 2014 | 7 | 0.510 |
Why?
|
| Polymorphism, Genetic | 5 | 2018 | 201 | 0.510 |
Why?
|
| Pericardial Effusion | 2 | 2015 | 6 | 0.500 |
Why?
|
| Alleles | 18 | 2018 | 352 | 0.500 |
Why?
|
| Retrospective Studies | 7 | 2026 | 2544 | 0.500 |
Why?
|
| Electroconvulsive Therapy | 1 | 2016 | 17 | 0.500 |
Why?
|
| Myositis, Inclusion Body | 1 | 2016 | 2 | 0.490 |
Why?
|
| Risk Factors | 32 | 2022 | 3994 | 0.490 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2016 | 3 | 0.480 |
Why?
|
| Leg Ulcer | 2 | 2013 | 8 | 0.480 |
Why?
|
| Dermatomyositis | 2 | 2014 | 9 | 0.470 |
Why?
|
| Warfarin | 2 | 2013 | 67 | 0.470 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2015 | 3 | 0.470 |
Why?
|
| Azathioprine | 1 | 2015 | 5 | 0.470 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2015 | 17 | 0.470 |
Why?
|
| Diphosphonates | 2 | 2014 | 19 | 0.460 |
Why?
|
| Bone Density Conservation Agents | 2 | 2014 | 28 | 0.460 |
Why?
|
| Anticoagulants | 2 | 2013 | 122 | 0.460 |
Why?
|
| Memory Disorders | 1 | 2016 | 77 | 0.460 |
Why?
|
| Osteonecrosis | 2 | 2013 | 8 | 0.460 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2015 | 2 | 0.450 |
Why?
|
| Adolescent | 25 | 2023 | 6081 | 0.450 |
Why?
|
| Insurance, Health | 2 | 2013 | 145 | 0.450 |
Why?
|
| Panniculitis, Peritoneal | 1 | 2014 | 1 | 0.450 |
Why?
|
| Mesentery | 1 | 2014 | 9 | 0.440 |
Why?
|
| Bronchial Fistula | 1 | 2014 | 2 | 0.440 |
Why?
|
| Pleural Diseases | 1 | 2014 | 3 | 0.440 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 245 | 0.440 |
Why?
|
| Genotype | 23 | 2015 | 800 | 0.430 |
Why?
|
| Bursitis | 1 | 2014 | 2 | 0.420 |
Why?
|
| Fractures, Spontaneous | 1 | 2014 | 6 | 0.420 |
Why?
|
| Antibodies, Antinuclear | 8 | 2016 | 17 | 0.420 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2014 | 21 | 0.420 |
Why?
|
| Endocarditis | 1 | 2014 | 11 | 0.420 |
Why?
|
| Patients | 1 | 2014 | 16 | 0.410 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2013 | 4 | 0.410 |
Why?
|
| Thrombosis | 6 | 2014 | 81 | 0.400 |
Why?
|
| Arm | 1 | 2013 | 28 | 0.400 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2013 | 10 | 0.400 |
Why?
|
| Polyneuropathies | 1 | 2013 | 9 | 0.390 |
Why?
|
| Complex Mixtures | 1 | 2012 | 9 | 0.390 |
Why?
|
| Osteoarthritis, Knee | 1 | 2013 | 15 | 0.390 |
Why?
|
| Age of Onset | 7 | 2020 | 114 | 0.390 |
Why?
|
| Nitrofurantoin | 1 | 2012 | 1 | 0.390 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2012 | 1 | 0.390 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2012 | 2 | 0.380 |
Why?
|
| Genetic Loci | 6 | 2013 | 104 | 0.380 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 67 | 0.380 |
Why?
|
| Osteoarthritis | 1 | 2013 | 25 | 0.380 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 249 | 0.380 |
Why?
|
| Education, Medical, Graduate | 1 | 2013 | 61 | 0.380 |
Why?
|
| Managed Care Programs | 1 | 2013 | 40 | 0.380 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 76 | 0.380 |
Why?
|
| Hand | 1 | 2013 | 34 | 0.380 |
Why?
|
| Obesity | 4 | 2016 | 1151 | 0.370 |
Why?
|
| Urinary Tract Infections | 1 | 2012 | 44 | 0.370 |
Why?
|
| Multiple Myeloma | 1 | 2012 | 48 | 0.360 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2012 | 11 | 0.360 |
Why?
|
| Anemia | 3 | 2007 | 55 | 0.360 |
Why?
|
| Hip Fractures | 1 | 2011 | 29 | 0.350 |
Why?
|
| Internship and Residency | 1 | 2013 | 146 | 0.350 |
Why?
|
| Health Literacy | 1 | 2014 | 130 | 0.340 |
Why?
|
| Dietary Supplements | 1 | 2012 | 213 | 0.340 |
Why?
|
| Logistic Models | 8 | 2017 | 1009 | 0.340 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 238 | 0.340 |
Why?
|
| Prognosis | 14 | 2021 | 861 | 0.330 |
Why?
|
| Prevalence | 10 | 2014 | 1612 | 0.310 |
Why?
|
| Socioeconomic Factors | 18 | 2016 | 1234 | 0.310 |
Why?
|
| Time Factors | 16 | 2021 | 1857 | 0.310 |
Why?
|
| Blood Sedimentation | 2 | 2007 | 4 | 0.310 |
Why?
|
| Angiography | 2 | 2021 | 15 | 0.300 |
Why?
|
| Drug Therapy, Combination | 4 | 2023 | 234 | 0.300 |
Why?
|
| Cytokines | 5 | 2012 | 678 | 0.300 |
Why?
|
| Age Factors | 16 | 2016 | 1154 | 0.300 |
Why?
|
| Depression | 1 | 2016 | 863 | 0.290 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2008 | 5 | 0.280 |
Why?
|
| Predictive Value of Tests | 7 | 2021 | 440 | 0.280 |
Why?
|
| Interferon Regulatory Factors | 3 | 2014 | 18 | 0.270 |
Why?
|
| DNA-Binding Proteins | 6 | 2014 | 561 | 0.270 |
Why?
|
| Odds Ratio | 7 | 2014 | 587 | 0.270 |
Why?
|
| Fever | 2 | 2021 | 62 | 0.270 |
Why?
|
| Sex Factors | 8 | 2014 | 1028 | 0.270 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2007 | 2 | 0.270 |
Why?
|
| Thrombocytosis | 1 | 2007 | 5 | 0.270 |
Why?
|
| Health Services | 1 | 2008 | 61 | 0.270 |
Why?
|
| Drug Prescriptions | 1 | 2008 | 60 | 0.260 |
Why?
|
| Giant Cell Arteritis | 1 | 2007 | 4 | 0.260 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2016 | 247 | 0.260 |
Why?
|
| Vitamin B Complex | 1 | 2006 | 5 | 0.250 |
Why?
|
| Acetylcarnitine | 1 | 2006 | 7 | 0.250 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2006 | 16 | 0.250 |
Why?
|
| STAT1 Transcription Factor | 2 | 2018 | 34 | 0.250 |
Why?
|
| Lymphopenia | 1 | 2006 | 17 | 0.250 |
Why?
|
| Mannose-Binding Lectin | 1 | 2006 | 6 | 0.250 |
Why?
|
| Chemokine CCL5 | 1 | 2006 | 41 | 0.250 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2026 | 5 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2026 | 1124 | 0.240 |
Why?
|
| Proteinuria | 5 | 2011 | 56 | 0.240 |
Why?
|
| Pharmaceutical Services | 1 | 2026 | 25 | 0.240 |
Why?
|
| C-Reactive Protein | 6 | 2014 | 167 | 0.240 |
Why?
|
| Immunoglobulin G | 3 | 2016 | 259 | 0.230 |
Why?
|
| Gingival Hemorrhage | 1 | 2024 | 2 | 0.220 |
Why?
|
| Regression Analysis | 5 | 2013 | 490 | 0.220 |
Why?
|
| Proportional Hazards Models | 10 | 2011 | 518 | 0.220 |
Why?
|
| Remission Induction | 2 | 2019 | 19 | 0.220 |
Why?
|
| Primary Health Care | 1 | 2008 | 380 | 0.210 |
Why?
|
| Linkage Disequilibrium | 9 | 2016 | 86 | 0.200 |
Why?
|
| Chronic Disease | 3 | 2021 | 549 | 0.200 |
Why?
|
| Lymphocyte Subsets | 2 | 1999 | 21 | 0.190 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2020 | 64 | 0.190 |
Why?
|
| Photosensitivity Disorders | 2 | 1999 | 5 | 0.190 |
Why?
|
| Methotrexate | 2 | 2016 | 22 | 0.190 |
Why?
|
| DNA | 7 | 2014 | 592 | 0.190 |
Why?
|
| Receptors, Complement 3d | 2 | 2014 | 4 | 0.190 |
Why?
|
| Synovial Membrane | 1 | 2022 | 3 | 0.190 |
Why?
|
| Elbow | 1 | 2022 | 4 | 0.190 |
Why?
|
| Telemedicine | 1 | 2026 | 234 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 587 | 0.180 |
Why?
|
| src-Family Kinases | 2 | 2014 | 49 | 0.180 |
Why?
|
| Molecular Motor Proteins | 2 | 2011 | 9 | 0.170 |
Why?
|
| Glomerular Filtration Rate | 3 | 2011 | 147 | 0.170 |
Why?
|
| Interleukin-10 | 2 | 2013 | 87 | 0.170 |
Why?
|
| Myosin Heavy Chains | 2 | 2011 | 18 | 0.170 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 2 | 2012 | 5 | 0.170 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 2 | 2012 | 8 | 0.170 |
Why?
|
| Histiocytic Necrotizing Lymphadenitis | 1 | 2001 | 5 | 0.170 |
Why?
|
| Hospitalization | 1 | 2025 | 485 | 0.170 |
Why?
|
| Cardiovascular Diseases | 5 | 2009 | 749 | 0.170 |
Why?
|
| Antibodies | 2 | 2015 | 144 | 0.170 |
Why?
|
| Minority Health | 1 | 2021 | 95 | 0.170 |
Why?
|
| Intestines | 1 | 2021 | 71 | 0.170 |
Why?
|
| Chromosomes, Human, X | 2 | 2012 | 23 | 0.170 |
Why?
|
| Antibodies, Anticardiolipin | 3 | 2013 | 6 | 0.160 |
Why?
|
| Texas | 7 | 2009 | 457 | 0.160 |
Why?
|
| Vaccination | 1 | 2023 | 355 | 0.160 |
Why?
|
| RNA, Messenger | 2 | 2023 | 1271 | 0.160 |
Why?
|
| Quantitative Trait Loci | 2 | 2018 | 88 | 0.160 |
Why?
|
| Activities of Daily Living | 1 | 2021 | 139 | 0.160 |
Why?
|
| Genetic Association Studies | 7 | 2015 | 118 | 0.160 |
Why?
|
| Gene Frequency | 8 | 2013 | 206 | 0.160 |
Why?
|
| Genome-Wide Association Study | 5 | 2016 | 423 | 0.160 |
Why?
|
| Ophthalmology | 1 | 2020 | 34 | 0.160 |
Why?
|
| Chromosome Mapping | 4 | 2013 | 199 | 0.150 |
Why?
|
| Sunscreening Agents | 1 | 1999 | 11 | 0.150 |
Why?
|
| Raynaud Disease | 2 | 2014 | 8 | 0.150 |
Why?
|
| Sunlight | 1 | 1999 | 48 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 223 | 0.150 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1998 | 20 | 0.150 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2009 | 11 | 0.150 |
Why?
|
| Phenotype | 8 | 2014 | 780 | 0.150 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1998 | 22 | 0.150 |
Why?
|
| STAT4 Transcription Factor | 1 | 2018 | 3 | 0.140 |
Why?
|
| Epidural Abscess | 1 | 2018 | 1 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 375 | 0.140 |
Why?
|
| Decompression, Surgical | 1 | 2018 | 5 | 0.140 |
Why?
|
| Gout Suppressants | 1 | 2018 | 6 | 0.140 |
Why?
|
| Exons | 3 | 2009 | 92 | 0.140 |
Why?
|
| HIV Infections | 2 | 2012 | 2586 | 0.140 |
Why?
|
| beta 2-Glycoprotein I | 2 | 2016 | 3 | 0.140 |
Why?
|
| Antigens, Bacterial | 1 | 1998 | 144 | 0.140 |
Why?
|
| Mutagenesis, Insertional | 1 | 2017 | 39 | 0.130 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1998 | 109 | 0.130 |
Why?
|
| Multifactorial Inheritance | 1 | 2017 | 34 | 0.130 |
Why?
|
| Seizures | 2 | 2008 | 79 | 0.130 |
Why?
|
| Sequence Deletion | 1 | 2017 | 93 | 0.130 |
Why?
|
| Acute Disease | 3 | 2012 | 155 | 0.130 |
Why?
|
| Membrane Proteins | 2 | 2012 | 561 | 0.130 |
Why?
|
| Toll-Like Receptor 7 | 2 | 2014 | 12 | 0.120 |
Why?
|
| Low Back Pain | 1 | 2018 | 101 | 0.120 |
Why?
|
| Immunoglobulin M | 1 | 2016 | 86 | 0.120 |
Why?
|
| Receptors, IgG | 2 | 2014 | 53 | 0.120 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 1 | 2016 | 2 | 0.120 |
Why?
|
| Minority Groups | 1 | 2021 | 690 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2018 | 263 | 0.120 |
Why?
|
| Illness Behavior | 3 | 2009 | 5 | 0.120 |
Why?
|
| Lupus Erythematosus, Discoid | 2 | 2012 | 2 | 0.120 |
Why?
|
| Pregnancy Complications | 2 | 2008 | 140 | 0.120 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2015 | 9 | 0.110 |
Why?
|
| Epidemiologic Methods | 7 | 2009 | 56 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2026 | 1600 | 0.110 |
Why?
|
| Interleukins | 2 | 2014 | 40 | 0.110 |
Why?
|
| Pericardium | 1 | 2015 | 15 | 0.110 |
Why?
|
| Fat Necrosis | 1 | 2014 | 3 | 0.110 |
Why?
|
| Penicillamine | 1 | 2014 | 5 | 0.110 |
Why?
|
| beta Karyopherins | 1 | 2014 | 4 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 2 | 2014 | 526 | 0.110 |
Why?
|
| Educational Status | 2 | 2014 | 339 | 0.110 |
Why?
|
| Leptin | 1 | 2015 | 118 | 0.110 |
Why?
|
| Incidence | 5 | 2009 | 1078 | 0.110 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2014 | 28 | 0.110 |
Why?
|
| Interleukin-2 | 2 | 2011 | 91 | 0.110 |
Why?
|
| Muscle Weakness | 1 | 2014 | 7 | 0.110 |
Why?
|
| Biopsy | 1 | 2014 | 177 | 0.100 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2013 | 12 | 0.100 |
Why?
|
| Echocardiography | 1 | 2015 | 167 | 0.100 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2013 | 27 | 0.100 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2013 | 1 | 0.100 |
Why?
|
| Bacteremia | 1 | 2014 | 37 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2016 | 321 | 0.100 |
Why?
|
| Social Class | 2 | 2014 | 291 | 0.100 |
Why?
|
| Immunoglobulin A | 1 | 2013 | 65 | 0.100 |
Why?
|
| Thrombophlebitis | 1 | 2013 | 2 | 0.100 |
Why?
|
| Deglutition Disorders | 1 | 2014 | 25 | 0.100 |
Why?
|
| Talus | 1 | 2013 | 1 | 0.100 |
Why?
|
| Fibula | 1 | 2013 | 2 | 0.100 |
Why?
|
| Arteries | 2 | 2014 | 81 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2012 | 200 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2013 | 48 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2013 | 96 | 0.100 |
Why?
|
| Tibia | 1 | 2013 | 26 | 0.100 |
Why?
|
| Infant | 1 | 2017 | 1175 | 0.100 |
Why?
|
| Bone Density | 1 | 2014 | 103 | 0.100 |
Why?
|
| Insurance Coverage | 1 | 2014 | 110 | 0.100 |
Why?
|
| Hemostasis | 1 | 2013 | 6 | 0.100 |
Why?
|
| Office Visits | 1 | 2013 | 28 | 0.100 |
Why?
|
| Weight Loss | 1 | 2014 | 137 | 0.100 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2013 | 25 | 0.100 |
Why?
|
| Databases, Factual | 3 | 2021 | 341 | 0.100 |
Why?
|
| Indians, South American | 1 | 2012 | 9 | 0.100 |
Why?
|
| Indians, North American | 2 | 2012 | 192 | 0.100 |
Why?
|
| Mixed Function Oxygenases | 1 | 2013 | 31 | 0.100 |
Why?
|
| Plasmapheresis | 1 | 2012 | 3 | 0.100 |
Why?
|
| Plasma Exchange | 1 | 2012 | 4 | 0.100 |
Why?
|
| Income | 1 | 2014 | 160 | 0.100 |
Why?
|
| DNA, Mitochondrial | 1 | 2014 | 191 | 0.100 |
Why?
|
| Staphylococcus aureus | 1 | 2014 | 94 | 0.100 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 53 | 0.100 |
Why?
|
| Health Status Indicators | 3 | 2007 | 90 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 2853 | 0.090 |
Why?
|
| Plasma | 1 | 2012 | 38 | 0.090 |
Why?
|
| Egg Proteins | 1 | 2012 | 4 | 0.090 |
Why?
|
| Child, Preschool | 1 | 2017 | 1546 | 0.090 |
Why?
|
| Ikaros Transcription Factor | 1 | 2012 | 9 | 0.090 |
Why?
|
| Demography | 3 | 2008 | 195 | 0.090 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2012 | 15 | 0.090 |
Why?
|
| Health Status | 2 | 2007 | 442 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 173 | 0.090 |
Why?
|
| Epistasis, Genetic | 1 | 2012 | 19 | 0.090 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2012 | 4 | 0.090 |
Why?
|
| Mexican Americans | 4 | 2009 | 226 | 0.090 |
Why?
|
| Apolipoproteins | 1 | 2011 | 22 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 235 | 0.090 |
Why?
|
| Poverty | 2 | 2013 | 400 | 0.090 |
Why?
|
| DNA Damage | 1 | 2014 | 356 | 0.090 |
Why?
|
| Radiography | 1 | 2011 | 71 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 83 | 0.090 |
Why?
|
| Vitamin D | 1 | 2014 | 196 | 0.090 |
Why?
|
| Protein Phosphatase 2 | 1 | 2011 | 26 | 0.090 |
Why?
|
| Health Behavior | 1 | 2016 | 575 | 0.090 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 48 | 0.090 |
Why?
|
| Complement C4 | 1 | 2011 | 4 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2011 | 7 | 0.090 |
Why?
|
| Complement Factor H | 1 | 2011 | 5 | 0.090 |
Why?
|
| Neoplasm Proteins | 2 | 2012 | 228 | 0.090 |
Why?
|
| Autoimmune Diseases | 2 | 2014 | 65 | 0.090 |
Why?
|
| Interferons | 1 | 2011 | 40 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2012 | 213 | 0.090 |
Why?
|
| Community Health Services | 1 | 2013 | 206 | 0.090 |
Why?
|
| Menopause | 2 | 2009 | 64 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 236 | 0.090 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2010 | 5 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 14 | 0.090 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 592 | 0.090 |
Why?
|
| Child | 2 | 2017 | 3443 | 0.080 |
Why?
|
| Exodeoxyribonucleases | 1 | 2011 | 17 | 0.080 |
Why?
|
| Calcium | 1 | 2014 | 491 | 0.080 |
Why?
|
| Sex Distribution | 2 | 2008 | 224 | 0.080 |
Why?
|
| Kidney | 2 | 2013 | 372 | 0.080 |
Why?
|
| Age Distribution | 2 | 2008 | 249 | 0.080 |
Why?
|
| Interferon Type I | 1 | 2010 | 18 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 90 | 0.080 |
Why?
|
| Protein Binding | 4 | 2015 | 1082 | 0.080 |
Why?
|
| Pregnancy Outcome | 2 | 2008 | 102 | 0.080 |
Why?
|
| Survival Rate | 3 | 2008 | 355 | 0.080 |
Why?
|
| Skin Diseases | 1 | 2010 | 30 | 0.080 |
Why?
|
| Hypertension | 2 | 2007 | 835 | 0.080 |
Why?
|
| Interleukin-21 Receptor alpha Subunit | 1 | 2009 | 1 | 0.080 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2009 | 2 | 0.080 |
Why?
|
| Cross-Over Studies | 2 | 2026 | 115 | 0.080 |
Why?
|
| snRNP Core Proteins | 2 | 2007 | 12 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2008 | 575 | 0.080 |
Why?
|
| Phosphoproteins | 1 | 2011 | 206 | 0.070 |
Why?
|
| Alabama | 2 | 2005 | 52 | 0.070 |
Why?
|
| DNA Replication | 1 | 2009 | 148 | 0.070 |
Why?
|
| Autoantigens | 2 | 2007 | 87 | 0.070 |
Why?
|
| Klinefelter Syndrome | 1 | 2008 | 3 | 0.070 |
Why?
|
| Alternative Splicing | 1 | 2009 | 94 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 333 | 0.070 |
Why?
|
| T-Lymphocytes | 3 | 2015 | 386 | 0.070 |
Why?
|
| Gene Dosage | 1 | 2008 | 75 | 0.070 |
Why?
|
| Menopause, Premature | 1 | 2008 | 6 | 0.070 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2008 | 78 | 0.070 |
Why?
|
| Myocarditis | 1 | 2008 | 24 | 0.070 |
Why?
|
| Language | 1 | 2009 | 185 | 0.070 |
Why?
|
| Th2 Cells | 2 | 2006 | 62 | 0.070 |
Why?
|
| Forms and Records Control | 1 | 2007 | 6 | 0.070 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2007 | 14 | 0.070 |
Why?
|
| Databases as Topic | 1 | 2007 | 25 | 0.070 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 42 | 0.070 |
Why?
|
| Acute-Phase Reaction | 1 | 2007 | 2 | 0.070 |
Why?
|
| Hypothyroidism | 1 | 2007 | 26 | 0.070 |
Why?
|
| Hypercholesterolemia | 1 | 2007 | 42 | 0.060 |
Why?
|
| Heroin Dependence | 1 | 2006 | 23 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2009 | 273 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2013 | 518 | 0.060 |
Why?
|
| Chemokine CCL3 | 1 | 2006 | 14 | 0.060 |
Why?
|
| Chemokine CCL4 | 1 | 2006 | 19 | 0.060 |
Why?
|
| Recurrence | 1 | 2007 | 152 | 0.060 |
Why?
|
| Intracranial Thrombosis | 1 | 2006 | 3 | 0.060 |
Why?
|
| Nephritis | 1 | 2006 | 7 | 0.060 |
Why?
|
| Mannose-Binding Lectins | 1 | 2006 | 14 | 0.060 |
Why?
|
| Puerperal Disorders | 1 | 2006 | 16 | 0.060 |
Why?
|
| Pedigree | 3 | 2016 | 94 | 0.060 |
Why?
|
| Pain | 1 | 2009 | 290 | 0.060 |
Why?
|
| Lung Diseases | 1 | 2007 | 63 | 0.060 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2006 | 14 | 0.060 |
Why?
|
| Disability Evaluation | 1 | 2006 | 73 | 0.060 |
Why?
|
| Cocaine-Related Disorders | 1 | 2006 | 102 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2006 | 124 | 0.060 |
Why?
|
| Ribonucleoproteins | 1 | 2006 | 31 | 0.060 |
Why?
|
| Lipoproteins, LDL | 1 | 2006 | 67 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 1081 | 0.060 |
Why?
|
| Ambulatory Care Facilities | 1 | 2026 | 68 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 163 | 0.060 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2005 | 1 | 0.060 |
Why?
|
| Psychology | 1 | 2005 | 39 | 0.060 |
Why?
|
| Pharmacists | 1 | 2026 | 61 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2006 | 139 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2005 | 33 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2026 | 165 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2026 | 259 | 0.060 |
Why?
|
| Sex Characteristics | 1 | 2007 | 258 | 0.060 |
Why?
|
| Base Sequence | 3 | 2012 | 983 | 0.060 |
Why?
|
| Bayes Theorem | 2 | 2015 | 126 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2006 | 242 | 0.050 |
Why?
|
| Forecasting | 1 | 2004 | 136 | 0.050 |
Why?
|
| Serositis | 1 | 2003 | 2 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 2 | 2007 | 125 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2012 | 1542 | 0.050 |
Why?
|
| Brazil | 1 | 2023 | 84 | 0.050 |
Why?
|
| CD40 Ligand | 2 | 2014 | 9 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2014 | 59 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2007 | 925 | 0.050 |
Why?
|
| Physical Examination | 1 | 2023 | 45 | 0.050 |
Why?
|
| Introns | 2 | 2013 | 79 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 2 | 1999 | 74 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2008 | 368 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2012 | 150 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2004 | 279 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2007 | 706 | 0.040 |
Why?
|
| Mice | 4 | 2015 | 6644 | 0.040 |
Why?
|
| Smoking | 2 | 2005 | 1024 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2021 | 68 | 0.040 |
Why?
|
| Animals | 5 | 2022 | 16992 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2021 | 74 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2026 | 497 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 113 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2014 | 384 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2009 | 1621 | 0.040 |
Why?
|
| B-Lymphocytes | 2 | 2012 | 189 | 0.040 |
Why?
|
| Aging | 1 | 2005 | 783 | 0.040 |
Why?
|
| Genetics, Population | 2 | 2012 | 121 | 0.040 |
Why?
|
| Clonal Anergy | 1 | 1999 | 5 | 0.040 |
Why?
|
| Clothing | 1 | 1999 | 9 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2014 | 430 | 0.040 |
Why?
|
| Exanthema | 1 | 1999 | 12 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 1998 | 29 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 1998 | 46 | 0.040 |
Why?
|
| Ultraviolet Rays | 1 | 1999 | 118 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 1998 | 68 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2014 | 863 | 0.040 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1999 | 129 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 1070 | 0.030 |
Why?
|
| HLA-DR Antigens | 2 | 2007 | 23 | 0.030 |
Why?
|
| Risk | 2 | 2008 | 287 | 0.030 |
Why?
|
| Antibodies, Antiphospholipid | 2 | 2006 | 3 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2006 | 162 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 611 | 0.030 |
Why?
|
| Receptors, Complement 3b | 1 | 2014 | 4 | 0.030 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2014 | 15 | 0.030 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2014 | 9 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 31 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2014 | 54 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2014 | 65 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 32 | 0.030 |
Why?
|
| NADH Dehydrogenase | 1 | 2013 | 6 | 0.030 |
Why?
|
| Glutathione Reductase | 1 | 2013 | 19 | 0.020 |
Why?
|
| Antigens, Nuclear | 1 | 2013 | 5 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 196 | 0.020 |
Why?
|
| Latin America | 1 | 2013 | 55 | 0.020 |
Why?
|
| Electron Transport Complex I | 1 | 2013 | 29 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2013 | 57 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 455 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2013 | 111 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 82 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 95 | 0.020 |
Why?
|
| Morbidity | 1 | 2012 | 97 | 0.020 |
Why?
|
| Genome, Human | 1 | 2013 | 144 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2012 | 43 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2012 | 38 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2012 | 74 | 0.020 |
Why?
|
| Oral Ulcer | 1 | 2011 | 3 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2012 | 75 | 0.020 |
Why?
|
| Research Design | 1 | 2014 | 385 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2011 | 12 | 0.020 |
Why?
|
| Pregnancy | 2 | 2008 | 1772 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2012 | 165 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2012 | 95 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 536 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 168 | 0.020 |
Why?
|
| Psychometrics | 1 | 2013 | 358 | 0.020 |
Why?
|
| Skin Physiological Phenomena | 1 | 2010 | 10 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2013 | 358 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 515 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 1035 | 0.020 |
Why?
|
| Portugal | 1 | 2009 | 10 | 0.020 |
Why?
|
| South America | 1 | 2009 | 24 | 0.020 |
Why?
|
| Spain | 1 | 2009 | 44 | 0.020 |
Why?
|
| Co-Repressor Proteins | 1 | 2009 | 19 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 386 | 0.020 |
Why?
|
| North America | 1 | 2009 | 85 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2014 | 735 | 0.020 |
Why?
|
| Glomerulonephritis | 1 | 2009 | 13 | 0.020 |
Why?
|
| Family | 1 | 2010 | 195 | 0.020 |
Why?
|
| Karyotyping | 1 | 2008 | 45 | 0.020 |
Why?
|
| Stillbirth | 1 | 2008 | 20 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2008 | 44 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 1869 | 0.020 |
Why?
|
| Abortion, Spontaneous | 1 | 2008 | 27 | 0.020 |
Why?
|
| Health Surveys | 1 | 2009 | 405 | 0.020 |
Why?
|
| HLA-DQ Antigens | 1 | 2007 | 6 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 758 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 317 | 0.020 |
Why?
|
| Sick Role | 1 | 2006 | 9 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 665 | 0.020 |
Why?
|
| Hepatitis B | 1 | 2006 | 41 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2006 | 97 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2006 | 73 | 0.020 |
Why?
|
| Premature Birth | 1 | 2008 | 95 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 247 | 0.020 |
Why?
|
| Homozygote | 1 | 2006 | 77 | 0.020 |
Why?
|
| Pneumonia | 1 | 2007 | 61 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2009 | 291 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 1177 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 153 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 51 | 0.010 |
Why?
|
| Apoptosis | 1 | 2013 | 1568 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 457 | 0.010 |
Why?
|
| Behavior | 1 | 2004 | 35 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 123 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 67 | 0.010 |
Why?
|
| Social Support | 1 | 2006 | 445 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2004 | 260 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 1455 | 0.010 |
Why?
|